Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelby D Reed

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 14, 2011
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemiaShelby D Reed
European Heart Journal|May 8, 2014
Statistical considerations in economic evaluations: a guide for cardiologistsShelby D Reed
European Heart Journal|July 20, 2012
How country-specific should a country-specific cost-effectiveness analysis be?Shelby D Reed
Diabetes Care|February 20, 2026
Comment on O'Hara et al. Understanding Patient Preferences Regarding Limb Salvage for Diabetic Foot Ulcers: A Discrete Choice Experiment. Diabetes Care 2025;48:1517-1523Shelby D Reed
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
A Beginner's Guide to Understanding Curative TherapiesDon Husereau, Shelby D Reed
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2020
Moving Beyond the Tip of the Iceberg to Incorporate Patients' Perspectives and Outcomes in the Medical Device Regulatory ProcessShelby D Reed, Lori McLeod
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory DecisionsShelby D Reed, Gabriela Lavezzari
Journal of Clinical and Translational Science|September 2, 2025
Expanding the use and interpretation of patient-centric cardiovascular clinical trial endpointsShelby D Reed, Pishoy Gouda
Cancer|June 8, 2012
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic modelShelby D Reed, Gary H Lyman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 29, 2009
Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancerShelby D Reed, Kevin A Schulman
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 14, 2011
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemiaShelby D Reed
European Heart Journal|May 8, 2014
Statistical considerations in economic evaluations: a guide for cardiologistsShelby D Reed
European Heart Journal|July 20, 2012
How country-specific should a country-specific cost-effectiveness analysis be?Shelby D Reed
Diabetes Care|February 20, 2026
Comment on O'Hara et al. Understanding Patient Preferences Regarding Limb Salvage for Diabetic Foot Ulcers: A Discrete Choice Experiment. Diabetes Care 2025;48:1517-1523Shelby D Reed
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
A Beginner's Guide to Understanding Curative TherapiesDon Husereau, Shelby D Reed
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2020
Moving Beyond the Tip of the Iceberg to Incorporate Patients' Perspectives and Outcomes in the Medical Device Regulatory ProcessShelby D Reed, Lori McLeod
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory DecisionsShelby D Reed, Gabriela Lavezzari
Journal of Clinical and Translational Science|September 2, 2025
Expanding the use and interpretation of patient-centric cardiovascular clinical trial endpointsShelby D Reed, Pishoy Gouda
Cancer|June 8, 2012
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic modelShelby D Reed, Gary H Lyman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 29, 2009
Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancerShelby D Reed, Kevin A Schulman
Pageof 22